10-Q: P3 Health Partners Faces Going Concern Doubt Amid Losses

P3 Health Partners Inc. reported increased net losses and declining revenue for Q2 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• P3 Health Partners Inc. reported a net loss of $43.7 million for the three months ended June 30, 2025, an increase from $28.8 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $87.9 million, up from $78.4 million in the prior year period.
• Total operating revenue decreased by 6% to $355.8 million for the three months ended June 30, 2025, and by 5% to $729.0 million for the six months ended June 30, 2025.
• Capitated revenue, which constitutes approximately 99% of total operating revenue, decreased by 6% to $351.7 million for the three months and by 5% to $721.2 million for the six months.
• The decrease in revenue was primarily driven by an 11% reduction in at-risk members, from 128,100 at June 30, 2024, to 114,100 at June 30, 2025, due to strategic termination of underperforming payor contracts and affiliate providers.
• Medical expense decreased by 4% to $351.4 million for the three months and by 3% to $723.4 million for the six months, largely due to the decrease in at-risk members.
• Premium deficiency reserve showed a benefit of $6.0 million for the three months and $12.9 million for the six months, but this change was attributed to management's assessment that increased medical expense is expected to increase future losses.
• Corporate, general and administrative expenses decreased by 12% to $23.3 million for the three months and by 11% to $48.3 million for the six months, primarily due to headcount reduction and the sale of Florida operations.
• Interest expense, net, significantly increased to $10.1 million for the three months and $18.9 million for the six months, compared to $5.4 million and $9.7 million respectively in the prior year periods.
• The company had $38.6 million in unrestricted cash as of June 30, 2025, and a working capital deficit of $348.5 million.
• A 1-for-50 reverse stock split was effected on April 11, 2025, to regain compliance with Nasdaq's minimum bid price requirement, which was achieved on April 29, 2025.
• The company completed the sale of its remaining Florida assets for approximately $0.1 million on May 1, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by increasing net losses, declining revenue and membership, a significant working capital deficit, and an explicit 'going concern' warning. While cost-cutting measures and new debt financing have been pursued, the high interest rates on new debt and the ongoing losses indicate a highly precarious financial position with substantial operational challenges and liquidity risks.

Positives

• Corporate, general and administrative expenses decreased by 12% for the three months and 11% for the six months ended June 30, 2025, driven by headcount reduction and the sale of Florida operations.
• The company regained compliance with Nasdaq's minimum bid price rule following a 1-for-50 reverse stock split.

Negatives

• Net loss increased significantly to $43.7 million for Q2 2025 and $87.9 million for the first six months of 2025, compared to prior year periods.
• Total operating revenue decreased by 6% for Q2 2025 and 5% for the first six months of 2025.
• At-risk membership declined by 11% year-over-year to 114,100 members, primarily due to strategic termination of underperforming contracts.
• Medical margin decreased to $30.6 million for Q2 2025 and $47.8 million for the first six months of 2025.
• Interest expense, net, nearly doubled for both the three and six-month periods ended June 30, 2025, reflecting increased debt.
• The company has a substantial working capital deficit of $348.5 million as of June 30, 2025.
• Management stated that increased medical expense is expected to increase future losses, despite a benefit from premium deficiency reserve.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to a history of net losses and insufficient cash resources.
• The company needs to raise additional capital to fund operations or refinance indebtedness, with no assurance such financing will be available on acceptable terms or at all.
• Inability to raise additional capital could force the company to curtail planned activities, discontinue operations, or sell assets, materially affecting its business and prospects.
• Risk of not being able to maintain compliance with debt covenants in the future, which could result in an event of default.
• Reliance on capitation payments from third-party payors, which could lead to delays, uncertainties, and disagreements regarding payments, including changes or reductions in Medicare reimbursement rates.
• Termination or non-renewal of Medicare Advantage contracts with health plans, or the company's contracts with those plans, could materially adversely affect revenue and operations.
• Dependence on affiliated professional entities and other physician partners to effectively manage quality and cost of care and perform obligations under payor contracts.
• Reductions in the quality ratings of health plans served could materially adversely affect business and financial results.
• Potential for information technology system failures, security breaches, cyberattacks, or deficiencies in cybersecurity to harm business and operations.
• Actual or perceived failures to comply with data protection, privacy, and security laws could adversely affect business and financial results.
• Failure to adhere to complex government laws and regulations in the heavily regulated healthcare industry could result in fines, penalties, operational changes, or adverse publicity.
• Arrangements with affiliated professional entities and physician partners could be found to constitute improper rendering of medical services or fee splitting under state laws.
• Audits and investigations under federal and state government programs could have adverse findings negatively affecting the business.
• Uncertain impact of recent healthcare legislation and other changes in the healthcare industry on business and financial results.
• The company's only significant asset is a minority economic interest in P3 LLC, which may not be sufficient to meet financial obligations or pay dividends.
• Obligation to make potentially significant payments under the Tax Receivable Agreement for certain tax benefits.
• Potential conflicts of interest due to the Sponsor and its affiliates not being limited in their ability to compete with the company.
• Risk of failing to meet the continued listing requirements of The Nasdaq Capital Market, potentially leading to delisting.
• Failure to maintain effective internal control over financial reporting could materially affect business, financial condition, results of operations, and stock price.

Future Outlook

The company expects to continue incurring net losses, comprehensive losses, and negative cash flows from operating activities. It believes its existing cash resources are not sufficient to support planned operations for at least the next year and is actively exploring raising additional capital through debt financing and equity issuances. There is no assurance that such financing will be available on favorable terms or at all, which could necessitate curtailing activities, discontinuing operations, or selling assets.

Management Comments

• We believe that the misaligned incentives in the fee-for-service (FFS) healthcare payment model and the fragmentation between physicians and care teams has led to sub-optimal clinical outcomes, limited access, high spending and unnecessary variability in the quality of care.
• We believe that a platform such as ours, which helps to realign incentives and focuses on treating the full patient, is uniquely positioned to address these healthcare challenges.
• Our contracted recurring revenue model offers us highly predictable revenue and rewards us for providing high-quality care rather than driving a high volume of services.
• When choosing a market to enter, we make our decision on a county-by-county basis across the United States. We look at various factors including: (i) population size, (ii) payor participants and concentration, (iii) health system participants and concentration, and (iv) competitive landscape.
• We expect that our PMPM revenue will continue to improve the longer members participate in our care model as we better understand and assess their health status (acuity) and coordinate their medical care.
• Our care model focuses on maintaining health and leveraging the primary care setting as a means of avoiding costly downstream healthcare costs, such as emergency department visits and acute hospital inpatient admissions.
• We expect our corporate, general and administrative expenses to increase in absolute dollars in the future as we continue to invest to support growth of our business, as well as due to the costs required to operate as a public company.

Industry Context

P3 Health Partners operates in the U.S. Medicare Advantage (MA) market, a significant segment of the broader Medicare market, which covered over 69 million eligible lives as of April 2025. The company's patient-centered, physician-led population health management model aims to address issues arising from the traditional fee-for-service (FFS) healthcare payment model by focusing on value-based care (VBC) and capitated arrangements. The reported decline in at-risk membership and revenue, despite strategic contract terminations, suggests challenges in a competitive and evolving MA landscape, where managing medical costs and member acuity is critical for profitability. The company's reliance on high-interest related-party debt indicates difficulty in securing traditional financing, potentially reflecting broader market skepticism towards VBC models struggling with profitability.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Corporate Governance

Legal Proceedings

• Received a Civil Investigative Demand (CID) from the United States Department of Justice (DOJ) in June 2024 under the False Claims Act. The CID requests documentation and information related to the marketing of broker programs and arrangements/remuneration paid to Medicare Advantage brokers, agents, and agencies, as well as arrangements with third parties. The company is cooperating with the investigation.

Related Party Transactions

• Entered into an unsecured promissory note (VGS 4 Promissory Note) with VBC Growth SPV 4, LLC (VGS 4), a related party, for up to $30.0 million at 19.5% interest, maturing August 13, 2028.
• Entered into an unsecured promissory note (VGS 5 Promissory Note) with VBC Growth SPV 5, LLC (VGS 5), a related party, for up to $70.0 million at 19.5% interest, maturing August 13, 2028.
• Both VGS 4 and VGS 5 Promissory Notes include up-front and back-end fees, and interest is effectively required to be paid in-kind due to subordination agreements with CRG Servicing LLC.
• The company has a master services agreement with Allymar Health Solutions, in which Chicago Pacific Founders (a principal equity holder) has an ownership interest, incurring $0.7 million in service expenses for Q2 2025 and $1.4 million for the six months ended June 30, 2025.
• The company has a managed behavioral health agreement with Nevada Behavioral Health Systems, in which Chicago Pacific Founders has an ownership interest, incurring an immaterial amount of service expense for Q2 2025 and the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity issuances and uncertainty regarding the company's ability to continue as a going concern, which could lead to further stock price depreciation.
• Employees may experience further headcount reductions as the company continues to manage costs and strategically exits underperforming operations.
• Customers (Medicare Advantage members) may experience changes in their healthcare providers or services due to the strategic termination of underperforming payor contracts and affiliate providers.
• Creditors, particularly those under the Term Loan Facility, have senior claims, while VGS 4 and VGS 5 promissory note holders are subordinated, indicating higher risk for these related-party lenders.
• Suppliers and other service providers may face payment risks given the company's working capital deficit and liquidity concerns.

Next Steps

• Continue efforts to raise additional capital through debt financing and equity issuances.
• Monitor and manage compliance with debt covenants under existing loan facilities.
• Cooperate with the Civil Investigative Demand from the United States Department of Justice regarding arrangements with insurance agents and brokers.
• Ongoing strategic reviews of provider and payor contracts, potentially leading to further exits of underperforming agreements.
• Potential future draws on the third tranche of the VGS 5 Promissory Note, subject to mutual agreement by December 31, 2025.

Key Dates

Recommendation

The company's financial health is severely deteriorated, marked by increasing net losses, declining revenue and membership, and a substantial working capital deficit. The explicit 'going concern' warning indicates a high probability of significant financial distress or potential bankruptcy within the next year. While the company is attempting to raise capital, the reliance on high-interest related-party debt and the ongoing operational challenges suggest a highly unfavorable risk-reward profile. A seasoned investor would recognize the significant downside risk and recommend divesting from this position.

Keywords

Medicare Advantage, Population Health Management, Value-Based Care, Healthcare, SEC Filing, 10-Q, Financial Results, Going Concern, Capitation, Medical Expense, Debt Financing, Nasdaq Listing, Risk Factors